The session explored the multifaceted approach to understanding prostate cancer, focusing on the metabolic changes induced by endocrine therapy. 

Research demonstrated that certain metabolites, particularly CXCL subtypes, not only reflect tumour progression but may also serve as prognostic indicators for treatment response. 

Moreover, environmental factors play a crucial role in influencing cancer outcomes, as identified by a cohort study linking specific chemical exposures to poor prognosis. The speaker emphasized the necessity of translating these findings into clinical practice through education and personalized treatment strategies. 

Looking forward, the research aims to validate these insights through larger-scale studies, ultimately enhancing clinical guidance for managing prostate cancer risks and improving patient outcomes.

Metabolic Alterations: Endocrine therapy significantly changes the metabolic profile in prostate cancer patients, with increased levels of specific metabolites, particularly CXCL subtypes, linked to tumour progression.

CXCL as a Prognostic Marker: The upregulation of the CXCL-X subtype post-endocrine therapy positions it as a potential prognostic marker, providing insights into managing therapy-resistant prostate cancer.

Environmental Impact: Dr. Yang talked about the environmental exposures, including chemicals like EPA and PCB, correlate with poor prostate cancer outcomes, emphasizing the need for further exploration of their long-term effects on tumour behaviour.

Translating Research into Practice: The research team is focused on developing educational strategies for patients and healthcare providers regarding environmental risks and integrating metabolic data into clinical workflows to personalize treatment.

Future Directions: Dr. Yang highlighted the importance of further research on CXCL involvement in therapy responses and the influence of environmental factors on prostate cancer prognosis, aiming to bridge the gap between basic research and clinical application.